Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
PTGX
Stock Latest News
Ratings
Protagonist Therapeutics’ Rusfertide: Promising Efficacy and Financial Upside Drive Buy Recommendation
8d ago
PTGX
Premium
Ratings
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera
8d ago
PTGX
Premium
The Fly
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
9d ago
TAK
PTGX
Premium
Ratings
Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
23d ago
PTGX
Premium
The Fly
Protagonist announces icotrokinra data from Phase 3 ICONIC-TOTAL study
1M ago
PTGX
Premium
Ratings
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating
1M ago
PTGX
Premium
Ratings
Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships
1M ago
PTGX
Premium
Ratings
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
1M ago
PTGX
Premium
The Fly
Protagonist Therapeutics reports Q1 EPS (19c), consensus 11c
1M ago
PTGX
Premium
Pre-Earnings
Is PTGX a Buy, Before Earnings?
1M ago
PTGX
Premium
Ratings
Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
2M ago
PTGX
Premium
Ratings
Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating
2M ago
PTGX
Premium
Ratings
Promising Prospects for Protagonist Therapeutics: Buy Rating Backed by Strong Icotrokinra Results and Pipeline Potential
2M ago
PTGX
Premium
The Fly
Protagonist announces data from subgroup analysis in ICONIC-LEAD study
2M ago
PTGX
Premium
Ratings
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song
2M ago
PTGX
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
AEON
APRE
Premium
The Fly
Protagonist Therapeutics price target raised to $70 from $58 at Wedbush
3M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $76 from $60 at Truist
3M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
3M ago
PTGX
Premium
The Fly
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
3M ago
PTGX
Premium
The Fly
Protagonist reports top line results from Phase 2b study of icotrokinra
3M ago
PTGX
Premium
Ratings
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies
3M ago
PTGX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
